AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22518827 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 10 mM l‐NAME + 20 mM capsazepine
Number of subjects: 12
Study 22518827 — intervention group
Group type: COMPARATOR
Intervention: 90% propylene glycol + 10% lactated Ringer (vehicle control)
Number of subjects: 12
Study 19020863 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing total knee arthroplasty (TKA)
Number of subjects: 25
Study 19020863 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing total knee arthroplasty (TKA)
Number of subjects: 25
Study 17166313 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Management Training program
Number of subjects: 49
Study 17166313 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 49
Study 14985863 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD patients
Number of subjects: 68
Study 14985863 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTR)
Number of subjects: 68
Study 12507112 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose irradiation (mean margin dose of 52.1 Gy)
Number of subjects: 64
Study 12507112 — intervention group
Group type: COMPARATOR
Intervention: Low-dose irradiation (mean margin dose of 41.5 Gy)
Number of subjects: 64
Study 9578044 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release carbamazepine (CBZ) twice daily
Number of subjects: 24
Study 9578044 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release carbamazepine (CBZ) four times daily
Number of subjects: 24
Study 9578044 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 7866473 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide
Number of subjects: 11
Study 7866473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2486640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen (Rengasil)
Number of subjects: 0
Study 2486640 — intervention group
Group type: COMPARATOR
Intervention: Piritramid (Dipidolar)
Number of subjects: 0
Study 33086 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (550 mg at first sign of pain, then 275 mg every six hours as needed)
Number of subjects: 32
Study 33086 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 32
Study 31026244 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Mass Index (LVMI)
Number of subjects: 709
Study 31026244 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative Wall Thickness (RWT)
Number of subjects: 709
Study 31026244 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Pressure (DBP and SBP)
Number of subjects: 709
Study 28549476 — intervention group
Group type: COMPARATOR
Intervention: Education only (non-tailored information only)
Number of subjects: 192
Study 28549476 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus intervention components to enhance motivation
Number of subjects: 192
Study 28549476 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus components to enhance motivation and self‐regulation
Number of subjects: 192
Study 28549476 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus components to enhance motivation, self‐regulation and habit formation
Number of subjects: 192
Study 24687684 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Caloric Diet (VLCD; Ø 600 kcal/day; n = 21)
Number of subjects: 38
Study 24687684 — intervention group
Group type: COMPARATOR
Intervention: Low Caloric Diet (LCD; Ø 1,200 kcal/day; n = 17)
Number of subjects: 38
Study 24687684 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VLCD and LCD
Number of subjects: 38
Study 23031209 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-caged (S-33)
Number of subjects: 50
Study 23031209 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-caged (S-42)
Number of subjects: 50
Study 23031209 — intervention group
Group type: COMPARATOR
Intervention: Group-housed (G)
Number of subjects: 50
Study 21757247 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-planned radiotherapy to 60Gy/40 fractions/2.5weeks (CHARTWEL)
Number of subjects: 406
Study 21757247 — intervention group
Group type: COMPARATOR
Intervention: 66Gy/33 fractions/6.5weeks (conventional fractionation, CF)
Number of subjects: 406
Study 21757247 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARTWEL
Number of subjects: 406
Study 21757247 — intervention group
Group type: COMPARATOR
Intervention: CF
Number of subjects: 406
Study 19225896 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional balance scale
Number of subjects: 0
Study 19225896 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement equivalence/invariance testing
Number of subjects: 0
Study 17140888 — intervention group
Group type: EXPERIMENTAL
Intervention: uUT‐EGD (5.2-mm-diameter videoscope)
Number of subjects: 120
Study 15271102 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous vancomycin infusion (CVI)
Number of subjects: 44
Study 15271102 — intervention group
Group type: COMPARATOR
Intervention: Intermittent vancomycin infusion (IVI)
Number of subjects: 44
Study 11554706 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturising cream applied for 14 days
Number of subjects: 13
Study 11554706 — intervention group
Group type: COMPARATOR
Intervention: Control skin
Number of subjects: 13
Study 9255718 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan (30 tablets, 45 mg/tablet, three times a day)
Number of subjects: 80
Study 9255718 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (1 week prior to chitosan ingestion)
Number of subjects: 80
Study 8332651 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg b.d. for two weeks
Number of subjects: 18
Study 8332651 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo for two weeks
Number of subjects: 18
Study 3089439 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (steroids) for 3 days
Number of subjects: 0
Study 3089439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30119677 — intervention group
Group type: EXPERIMENTAL
Intervention: Robenacoxib 2mg/kg
Number of subjects: 32
Study 30119677 — intervention group
Group type: EXPERIMENTAL
Intervention: Robenacoxib 6mg/kg
Number of subjects: 32
Study 30119677 — intervention group
Group type: EXPERIMENTAL
Intervention: Robenacoxib 10mg/kg
Number of subjects: 32
Study 30119677 — intervention group
Group type: COMPARATOR
Intervention: Sham control (0mg/kg)
Number of subjects: 32
Study 26381059 — intervention group
Group type: EXPERIMENTAL
Intervention: PART-O scoring modifications
Number of subjects: 469
Study 24595149 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml (15 mg) 0.5% isobaric levobupivacaine (group L)
Number of subjects: 100
Study 24595149 — intervention group
Group type: COMPARATOR
Intervention: 3 ml (15 mg) of 0.5% hyperbaric bupivacaine (group B)
Number of subjects: 100
Study 21929835 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (1·67 g EPA + 0·16 g DHA/d)
Number of subjects: 50
Study 21929835 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (1·55 g DHA + 0·40 g EPA/d)
Number of subjects: 50
Study 21929835 — intervention group
Group type: COMPARATOR
Intervention: LA (2·2 g/d)
Number of subjects: 50
Study 20197484 — intervention group
Group type: EXPERIMENTAL
Intervention: Necitumumab 800 mg (flat dosing)
Number of subjects: 60
Study 20197484 — intervention group
Group type: EXPERIMENTAL
Intervention: Necitumumab 600 mg or more
Number of subjects: 60
Study 20197484 — intervention group
Group type: EXPERIMENTAL
Intervention: Necitumumab 1000 mg every 2 weeks
Number of subjects: 60
Study 18806204 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied NTG ointment (2%)
Number of subjects: 75
Study 18806204 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied NTG ointment (2%) + treadmill ambulation
Number of subjects: 75
Study 18806204 — intervention group
Group type: COMPARATOR
Intervention: Treadmill ambulation only
Number of subjects: 75
Study 16894463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg daily (before July 1999) or Clopidogrel 75 mg daily (after July 1999) for one month
Number of subjects: 1548
Study 16894463 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 1548
Study 16894463 — intervention group
Group type: EXPERIMENTAL
Intervention: Killip class >1 on admission
Number of subjects: 1548
Study 16894463 — intervention group
Group type: EXPERIMENTAL
Intervention: SAT presence
Number of subjects: 1548
Study 12772817 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberogast
Number of subjects: 592
Study 12772817 — intervention group
Group type: COMPARATOR
Intervention: Placebo or cisapride (positive control)
Number of subjects: 592
Study 11508070 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 78
Study 11508070 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian diet
Number of subjects: 78
Study 8851903 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic plus exercise training (D+E)
Number of subjects: 9
Study 8851903 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (D)
Number of subjects: 9
Study 8851903 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 9
Study 1626605 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective vagotomy with pyloroplasty
Number of subjects: 161
Study 1626605 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy with pyloroplasty
Number of subjects: 161
Study 1626605 — intervention group
Group type: COMPARATOR
Intervention: Selective proximal vagotomy alone
Number of subjects: 161
Study 6647208 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol SA (Astra)
Number of subjects: 8
Study 6647208 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 8
Study 6647208 — intervention group
Group type: COMPARATOR
Intervention: metoprolol SR
Number of subjects: 8
Study 6647208 — intervention group
Group type: COMPARATOR
Intervention: conventional metoprolol
Number of subjects: 8
Study 6647208 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol (all formulations)
Number of subjects: 8
Study 6647208 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 8
Study 31203725 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine treatment
Number of subjects: 58
Study 30153852 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional suture-bridge technique
Number of subjects: 100
Study 30153852 — intervention group
Group type: EXPERIMENTAL
Intervention: Knotless suture-bridge technique
Number of subjects: 100
Study 27088053 — intervention group
Group type: EXPERIMENTAL
Intervention: Taiji beginner course (Yang-Style Taiji, 2 hours per week, 12 weeks)
Number of subjects: 70
Study 27088053 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list for the course)
Number of subjects: 70
Study 25192882 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management programme including physical exercise and dietary restriction
Number of subjects: 0
Study 25192882 — intervention group
Group type: COMPARATOR
Intervention: No change comparator (control)
Number of subjects: 0
Study 25192882 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management programme
Number of subjects: 0
Study 22580255 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 274
Study 22580255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 274
Study 22580255 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (Control)
Number of subjects: 274
Study 22580255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled DES (Paclitaxel and Sirolimus)
Number of subjects: 274
Study 20646099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 300,000 IU every 3 months (intermittent D(3) group)
Number of subjects: 60
Study 20646099 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol 1,000 IU/day (daily D(3) group)
Number of subjects: 60
Study 20646099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 17356080 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 3911
Study 17356080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3911
Study 15754269 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of modified‐release aspirin daily
Number of subjects: 448
Study 15754269 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of simvastatin daily
Number of subjects: 448
Study 12130413 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair
Number of subjects: 24
Study 12130413 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 24
Study 10425885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium naproxen
Number of subjects: 18
Study 10425885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7558992 — intervention group
Group type: EXPERIMENTAL
Intervention: S-R compatibility auditory task
Number of subjects: 10
Study 1975322 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (tPA)
Number of subjects: 20891
Study 1975322 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (SK)
Number of subjects: 20891
Study 1975322 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 20891
Study 1975322 — intervention group
Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 20891
Study 7023526 — intervention group
Group type: EXPERIMENTAL
Intervention: SHRZ6 and EHRZ6 regimens (6 months, daily isoniazid and rifampicin, supplemented by streptomycin and pyrazinamide for the first two months)
Number of subjects: 444
Study 7023526 — intervention group
Group type: COMPARATOR
Intervention: EHR9 regimen (9 months, daily isoniazid and rifampicin, supplemented by ethambutol for the first two months)
Number of subjects: 444
Study 7023526 — intervention group
Group type: EXPERIMENTAL
Intervention: SHRZ6 and EHRZ6 regimens (6 months, daily isoniazid and rifampicin, supplemented by pyrazinamide)
Number of subjects: 444
Study 7023526 — intervention group
Group type: COMPARATOR
Intervention: EHR9 regimen (9 months, daily isoniazid and rifampicin, supplemented by ethambutol)
Number of subjects: 444
Study 30918097 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofinetide 200 mg/kg bid
Number of subjects: 82
Study 30918097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 30096080 — intervention group
Group type: EXPERIMENTAL
Intervention: Fix for Life (F4L) cadavers
Number of subjects: 30
Study 30096080 — intervention group
Group type: COMPARATOR
Intervention: SimMan 3G manikin
Number of subjects: 30
Study 30096080 — intervention group
Group type: COMPARATOR
Intervention: Formalin-fixed cadavers
Number of subjects: 30
Study 27300156 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad Target Speech Recasts (BTSR)
Number of subjects: 51
Study 27300156 — intervention group
Group type: COMPARATOR
Intervention: Contrast treatment
Number of subjects: 51
Study 25195684 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal liver support therapy
Number of subjects: 86
Study 22443312 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty
Number of subjects: 0
Study 22443312 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical care
Number of subjects: 0
Study 18708192 — intervention group
Group type: EXPERIMENTAL
Intervention: One-lung ventilation (OLV)
Number of subjects: 30
Study 18708192 — intervention group
Group type: COMPARATOR
Intervention: 2-lung ventilation (TLV)
Number of subjects: 30
Study 17767632 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume breathing using an O(2) flow of 9 l x min(‐1) for 3 min (TV x 3 min)
Number of subjects: 20
Study 17767632 — intervention group
Group type: COMPARATOR
Intervention: Four deep breaths within 30 s using an O(2) flow of 15 l x min(‐1) (4 DB)
Number of subjects: 20
Study 17767632 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight deep breaths within 1 min using an O(2) flow of 15 l x min(‐1) (8 DB)
Number of subjects: 20
Study 15554760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (target dose = 200 mg/day, minimum dose = 100 mg/day)
Number of subjects: 1315
Study 11592671 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 mg)
Number of subjects: 50
Study 11592671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (10 mg)
Number of subjects: 50
Study 11592671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11592671 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 50
Study 11592671 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (.07%)
Number of subjects: 50
Study 11592671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (10 mg) under no fatigue
Number of subjects: 50
Study 11592671 — intervention group
Group type: COMPARATOR
Intervention: Placebo under fatigue
Number of subjects: 50
Study 9775640 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightguard vital bleaching using carbamide peroxide (up to 10 percent)
Number of subjects: 12
Study 9775640 — intervention group
Group type: EXPERIMENTAL
Intervention: Two nightguard bleaching systems
Number of subjects: 12
Study 7842531 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3 gm EPA and 2 gm DHA daily)
Number of subjects: 20
Study 7842531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 20
Study 3585610 — intervention group
Group type: EXPERIMENTAL
Intervention: PMN transfusions (15 mL/kg containing 0.5 to 1.0 X 10(9) PMN, one transfusion every 12 hours for a total of five transfusions)
Number of subjects: 35
Study 3585610 — intervention group
Group type: COMPARATOR
Intervention: Non-transfused group
Number of subjects: 35
Study 3585610 — intervention group
Group type: EXPERIMENTAL
Intervention: PMN transfusions
Number of subjects: 35
Study 3585610 — intervention group
Group type: EXPERIMENTAL
Intervention: Low circulating levels of total hemolytic complement
Number of subjects: 35
Study 30185930 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous cueing with predictable cue-target onset asynchronies (CTOAs)
Number of subjects: 0
Study 30185930 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous cueing with randomized CTOAs
Number of subjects: 0
Study 30185930 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in pupil size to the cue
Number of subjects: 0
Study 30185930 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic curvature
Number of subjects: 0
Study 30185930 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsaccades
Number of subjects: 0
Study 30185930 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention measures when facilitation is absent
Number of subjects: 0
Study 28093442 — intervention group
Group type: EXPERIMENTAL
Intervention: CS1002 (Unicough)
Number of subjects: 163
Study 28093442 — intervention group
Group type: COMPARATOR
Intervention: Simple Linctus (SL)
Number of subjects: 163
Study 25162407 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS device
Number of subjects: 23
Study 25162407 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 23
Study 23358809 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated and tailored return-to-work intervention
Number of subjects: 168
Study 23358809 — intervention group
Group type: COMPARATOR
Intervention: Conventional case management
Number of subjects: 168
Study 21596903 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (culturally targeted materials and telephone‐based motivational interviewing)
Number of subjects: 1021
Study 21596903 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (standard educational materials)
Number of subjects: 1021
Study 21596903 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (culturally targeted materials)
Number of subjects: 1021
Study 18081808 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo-activated disinfection (PAD)
Number of subjects: 38
Study 18081808 — intervention group
Group type: COMPARATOR
Intervention: Laser alone
Number of subjects: 38
Study 18081808 — intervention group
Group type: COMPARATOR
Intervention: Dye without laser
Number of subjects: 38
Study 12752512 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 U of botulinum toxin type A
Number of subjects: 59
Study 12752512 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 U of botulinum toxin type A
Number of subjects: 59
Study 12752512 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 U of botulinum toxin type A
Number of subjects: 59
Study 12752512 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 59
Study 10544442 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 148
Study 10544442 — intervention group
Group type: COMPARATOR
Intervention: Atgam
Number of subjects: 148
Study 7774757 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (4 to 6 g/day)
Number of subjects: 45
Study 7774757 — intervention group
Group type: EXPERIMENTAL
Intervention: High-lipase pancreatin (9 g/day)
Number of subjects: 45
Study 7774757 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial pancreatic enzyme preparations (12 to 24 tablets or 9.0 g)
Number of subjects: 45
Study 7774757 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (50 mg)
Number of subjects: 45
Study 1964664 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fixed doses of a low‐molecular‐weight heparin (CY216; 225 IC anti‐Xa U/kg 12 hourly) for 10 days
Number of subjects: 90
Study 1964664 — intervention group
Group type: COMPARATOR
Intervention: Intravenous adjusted unfractionated heparin (UFH)
Number of subjects: 90
Study 1964664 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CY216 and UFH)
Number of subjects: 90
Study 227077 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride
Number of subjects: 130
Study 227077 — intervention group
Group type: COMPARATOR
Intervention: Dimetotiazine
Number of subjects: 130
Study 31832876 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin tromethamine (FT)
Number of subjects: 61
Study 31832876 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime sodium (control)
Number of subjects: 61
Study 31369185 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine (LC) supplementation 2 g for 8 weeks
Number of subjects: 48
Study 31369185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48